Fig. 2

Effect of VitE on DC maturation. a Original dot plots representing the percentage of CD11c⁺CD86⁺ control-(1st line) and klotho-silenced (2nd line) DCs is shown prior to control (1st panel) and 24 h following treatment with LPS (100 ng/ml) either in the absence (2nd panel) or presence of VitE (3rd panel). b Arithmetic mean ± SEM (n = 5) of CD11c⁺CD86⁺ cells is shown prior to control (1st panel) and 24 h following treatment with LPS (100 ng/ml) either in the absence (2nd bar) or presence of VitE (3rd bar) or presence of VitE and Bay 11-7082 (10 µM) (4th bar). c Arithmetic mean ± SEM (n = 4) of CD11c⁺CD86⁺ cells transfected with klotho siRNA is shown prior to control (1st panel) and 24 h following treatment with LPS (100 ng/ml) either in the absence (2nd bar) or presence (3rd bar) of VitE. d, g Arithmetic mean ± SEM (n = 5–7) of IL12p70 and TNF-α production in DCs are shown prior to control (white bar) and 24 h following treatment with LPS (100 ng/ml) either in the absence (2nd bar) or presence of VitE (3rd bar) or presence of VitE and Bay 11-7082 (10 µM) (4th bar). e, h Arithmetic mean ± SEM (n = 5–7) of IL12p70 and TNF-α production in DCs transfected with klotho siRNA are shown prior to control (1st bar) and 24 h following treatment with LPS (100 ng/ml) either in the absence (2nd bar) or presence (3rd bar) of VitE. f Original dot plots representing the percentage of CD11c⁺IL-12p70⁺ control-(1st line) and klotho-silenced (2nd line) DCs is shown prior to control (1st panel) and 24 h following treatment with LPS (100 ng/ml) either in the absence (2nd panel) or presence of VitE (3rd panel). *(p < 0.05) represents significant difference from LPS-stimulated DCs; ^##(p < 0.01) and ^###(p < 0.001) indicate significant difference from LPS and VitE- treated DCs (ANOVA)